Literature DB >> 6460829

Immunoregulation of murine myeloma in vitro. II. Suppression of MOPC-315 immunoglobulin secretion and synthesis by idiotype-specific suppressor T cells.

G L Milburn, R G Lynch.   

Abstract

In previous studies, BALB/c mice immunized with trinitrophenyl-specific IgA protein (M315) produced by MOPC-315 developed idiotype (Id315)-specific T cells that suppressed M315 secretion in vivo. In the present in vitro studies, we show that inhibition of M315 secretion is mediated by a theta,Lyt-1-2+ cell that expresses a surface membrane receptor for Id315. The suppressor signal is a diffusable product that acts directly on M315-secreting myeloma cells. Inhibition of M315 secretion is T cell dose-dependent, Id315-specific, reversible, and occurs without any effect on MOPC-315 growth, viability, or surface membrane expression of M315. Inhibition of M315 secretion results from a selective inhibition of M315 synthesis in the myeloma cell. These studies provide new insight into the mechanisms of direct B cell regulation by idiotype-specific T cells.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6460829      PMCID: PMC2186615          DOI: 10.1084/jem.155.3.852

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  24 in total

1.  Myeloma-specific antibodies: studies of their properties and their relationship to tumor immunity.

Authors:  M J Frikke; S H Bridges; R G Lynch
Journal:  J Immunol       Date:  1977-06       Impact factor: 5.422

2.  Myeloma cell immunoglobulin expression during in vivo growth in diffusion chambers: evidence for repetitive cycles of differentiation.

Authors:  J W Rohrer; K Vasa; R G Lynch
Journal:  J Immunol       Date:  1977-09       Impact factor: 5.422

3.  Late acting T cell depression of high avidity IgG antibody secretion in the secondary response.

Authors:  R W Warren; J M Davie
Journal:  J Immunol       Date:  1977-11       Impact factor: 5.422

4.  Immunologic functions of isolated human lymphocyte subpopulations. I. Quantitative isolation of human T and B cells and response to mitogens.

Authors:  L Chess; R P MacDermott; S F Schlossman
Journal:  J Immunol       Date:  1974-10       Impact factor: 5.422

5.  Stability of cytoplasmic ribonucleic acid in a mouse myeloma: estimation of the half-life of the messenger RNA coding for an immunoglobulin light chain.

Authors:  N J Cowan; C Milstein
Journal:  J Mol Biol       Date:  1974-02-05       Impact factor: 5.469

6.  Towards a network theory of the immune system.

Authors:  N K Jerne
Journal:  Ann Immunol (Paris)       Date:  1974-01

7.  Studies of the mechanism of tunicamycin in hibition of IgA and IgE secretion by plasma cells.

Authors:  S Hickman; A Kulczycki; R G Lynch; S Kornfeld
Journal:  J Biol Chem       Date:  1977-06-25       Impact factor: 5.157

8.  Myeloma proteins as tumor-specific transplantation antigens.

Authors:  R G Lynch; R J Graff; S Sirisinha; E S Simms; H N Eisen
Journal:  Proc Natl Acad Sci U S A       Date:  1972-06       Impact factor: 11.205

9.  Cell-bound myeloma proteins on the surface of myeloma cells: potential targets for the immune system.

Authors:  K Hannestad; M S Kao; H N Eisen
Journal:  Proc Natl Acad Sci U S A       Date:  1972-08       Impact factor: 11.205

10.  Presence on idiotype-specific suppressor T cells of receptors that interact with molecules bearing the idiotype.

Authors:  F L Owen; S T Ju; A Nisonoff
Journal:  J Exp Med       Date:  1977-06-01       Impact factor: 14.307

View more
  11 in total

1.  In vitro inhibition of tumor B cell growth by IgG-BF-producing Fc gamma RII+ T cell hybridoma and by immunoglobulin G-binding factors.

Authors:  C Mathiot; S Amigorena; J Moncuit; C Sautès; W H Fridman; J L Teillaud
Journal:  Immunol Res       Date:  1992       Impact factor: 2.829

Review 2.  Differentiation and cancer: the conditional autonomy of phenotype.

Authors:  R G Lynch
Journal:  Proc Natl Acad Sci U S A       Date:  1995-01-31       Impact factor: 11.205

3.  In vitro synthesis of IgE by human lymphocytes. IV. Suppression of the spontaneous IgE synthesis by IgE-binding factors secreted by tunicamycin-treated RPMI 8866 cells.

Authors:  M Sarfati; E Rector; A H Sehon; G Delespesse
Journal:  Immunology       Date:  1984-12       Impact factor: 7.397

4.  Immune response to myeloma cells and idiotypes.

Authors:  A K Abbas
Journal:  Surv Immunol Res       Date:  1983

5.  Generation of T cell clones binding F(ab')2 fragments of the idiotypic immunoglobulin in patients with monoclonal gammopathy.

Authors:  A Osterborg; M Masucci; S Bergenbrant; G Holm; A K Lefvert; H Mellstedt
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

6.  Selective elimination of idiotype-binding cells in vivo by a drug-idiotype conjugate demonstrates the functional significance of these cells in immune regulation.

Authors:  M M Abu-Hadid; R B Bankert; G L Mayers
Journal:  Proc Natl Acad Sci U S A       Date:  1988-06       Impact factor: 11.205

7.  Chemical synthesis of idiotopes. Evidence that antisera to the same JH1 peptide detect multiple binding site-associated idiotopes.

Authors:  M V Seiden; B Clevinger; S McMillan; A Srouji; R Lerner; J M Davie
Journal:  J Exp Med       Date:  1984-05-01       Impact factor: 14.307

8.  Induction of idiotype-specific suppressor T cells with antigen/antibody complexes.

Authors:  M J Caulfield; K J Luce; M R Proffitt; J Cerny
Journal:  J Exp Med       Date:  1983-06-01       Impact factor: 14.307

9.  Consumption of monoclonal anti-idiotypic antibody by neoplastic B lymphocytes: a guide for immunotherapy.

Authors:  F K Stevenson; M J Glennie; D M Johnston; A L Tutt; G T Stevenson
Journal:  Br J Cancer       Date:  1984-09       Impact factor: 7.640

10.  T lymphocyte-mediated suppression of myeloma function in vitro. IV. Generation of effector suppressor cells specific for myeloma idiotypes.

Authors:  A K Abbas; M Takaoki; M I Greene
Journal:  J Exp Med       Date:  1982-04-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.